Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum (original) (raw)

. 1996 Jan 15;15(2):418–428.

Abstract

Unlike class I histocompatibility (MHC) antigens, most newly synthesized MHC class II molecules fail to be loaded with peptides in the endoplasmic reticulum (ER), binding instead to the invariant chain glycoprotein (Ii). Ii blocks the class II peptide binding groove until the class II:Ii complexes are transported to endosomes where Ii is removed by proteolysis, thus permitting loading with endosomal short peptides (approximately 12-25 amino acids). Ligands from which the groove is protected by Ii have not yet been identified; theoretically they could be short peptides or longer polypeptides (or both), because the class II groove is open at both ends. Here we show that in Ii- deficient cells, but not in cells expressing large amounts of Ii, a substantial fraction of class II alpha beta dimers forms specific, SDS-resistant 1:1 complexes with a variety of polypeptides. Different sets of polypeptides bound to H-2Ak, Ek, Ed and HLA-DR1 class II molecules; for Ak, a major species of Mr 50 kDa (p50) and further distinct 20 and 130 kDa polypeptides were detectable. Class II binding of p50 was characterized in detail. Point mutations within the Ak antigen binding groove destabilized the p50:class II complexes; a mutation outside the groove had no effect. A short segment of p50 was sufficient for association with Ak. The p50 polypeptide was synthesized endogenously, bound to Ak in a pre-Golgi compartment, and was transported to the cell surface in association with Ak. Thus, Ii protects the class II groove from binding endogenous, possibly misfolded polypeptides in the ER. The possibility is discussed that polypeptide binding is an ancestral function of the MHC antigen binding domain.

418

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altmann D. M., Heyes J. M., Ikeda H., Sadler A. M., Wilkinson D., Madrigal J. A., Bodmer J. G., Trowsdale J. Fine mapping of HLA class II monoclonal antibody specificities using transfected L cells. Immunogenetics. 1990;32(1):51–55. doi: 10.1007/BF01787329. [DOI] [PubMed] [Google Scholar]
  2. Anderson K. S., Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J. 1994 Feb 1;13(3):675–682. doi: 10.1002/j.1460-2075.1994.tb06306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson M. S., Miller J. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2282–2286. doi: 10.1073/pnas.89.6.2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Avva R. R., Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity. 1994 Dec;1(9):763–774. doi: 10.1016/s1074-7613(94)80018-9. [DOI] [PubMed] [Google Scholar]
  5. Barnstable C. J., Bodmer W. F., Brown G., Galfre G., Milstein C., Williams A. F., Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 1978 May;14(1):9–20. doi: 10.1016/0092-8674(78)90296-9. [DOI] [PubMed] [Google Scholar]
  6. Bertolino P., Forquet F., Pont S., Koch N., Gerlier D., Rabourdin-Combe C. Correlation between invariant chain expression level and capability to present antigen to MHC class II-restricted T cells. Int Immunol. 1991 May;3(5):435–443. doi: 10.1093/intimm/3.5.435. [DOI] [PubMed] [Google Scholar]
  7. Bijlmakers M. J., Benaroch P., Ploegh H. L. Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBO J. 1994 Jun 1;13(11):2699–2707. doi: 10.1002/j.1460-2075.1994.tb06560.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bikoff E. K., Huang L. Y., Episkopou V., van Meerwijk J., Germain R. N., Robertson E. J. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J Exp Med. 1993 Jun 1;177(6):1699–1712. doi: 10.1084/jem.177.6.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bodmer H., Viville S., Benoist C., Mathis D. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science. 1994 Mar 4;263(5151):1284–1286. doi: 10.1126/science.7510069. [DOI] [PubMed] [Google Scholar]
  10. Bonnerot C., Marks M. S., Cosson P., Robertson E. J., Bikoff E. K., Germain R. N., Bonifacino J. S. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain. EMBO J. 1994 Feb 15;13(4):934–944. doi: 10.1002/j.1460-2075.1994.tb06338.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bouvier M., Wiley D. C. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science. 1994 Jul 15;265(5170):398–402. doi: 10.1126/science.8023162. [DOI] [PubMed] [Google Scholar]
  12. Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993 Jul 1;364(6432):33–39. doi: 10.1038/364033a0. [DOI] [PubMed] [Google Scholar]
  13. Busch R., Vturina I. Y., Drexler J., Momburg F., Hämmerling G. J. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur J Immunol. 1995 Jan;25(1):48–53. doi: 10.1002/eji.1830250110. [DOI] [PubMed] [Google Scholar]
  14. Capps G. G., Robinson B. E., Lewis K. D., Zúiga M. C. In vivo dimeric association of class I MHC heavy chains. Possible relationship to class I MHC heavy chain-beta 2-microglobulin dissociation. J Immunol. 1993 Jul 1;151(1):159–169. [PubMed] [Google Scholar]
  15. Clements V. K., Baskar S., Armstrong T. D., Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol. 1992 Oct 1;149(7):2391–2396. [PubMed] [Google Scholar]
  16. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol. 1994;12:259–293. doi: 10.1146/annurev.iy.12.040194.001355. [DOI] [PubMed] [Google Scholar]
  17. Dellabona P., Peccoud J., Kappler J., Marrack P., Benoist C., Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell. 1990 Sep 21;62(6):1115–1121. doi: 10.1016/0092-8674(90)90388-u. [DOI] [PubMed] [Google Scholar]
  18. Dodi A. I., Brett S., Nordeng T., Sidhu S., Batchelor R. J., Lombardi G., Bakke O., Lechler R. I. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. Eur J Immunol. 1994 Jul;24(7):1632–1639. doi: 10.1002/eji.1830240727. [DOI] [PubMed] [Google Scholar]
  19. Elliott E. A., Drake J. R., Amigorena S., Elsemore J., Webster P., Mellman I., Flavell R. A. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med. 1994 Feb 1;179(2):681–694. doi: 10.1084/jem.179.2.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Flajnik M. F., Canel C., Kramer J., Kasahara M. Which came first, MHC class I or class II? Immunogenetics. 1991;33(5-6):295–300. doi: 10.1007/BF00216688. [DOI] [PubMed] [Google Scholar]
  21. Germain R. N., Hendrix L. R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 1991 Sep 12;353(6340):134–139. doi: 10.1038/353134a0. [DOI] [PubMed] [Google Scholar]
  22. Germain R. N., Margulies D. H. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993;11:403–450. doi: 10.1146/annurev.iy.11.040193.002155. [DOI] [PubMed] [Google Scholar]
  23. Germain R. N., Rinker A. G., Jr Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature. 1993 Jun 24;363(6431):725–728. doi: 10.1038/363725a0. [DOI] [PubMed] [Google Scholar]
  24. Goding J. W. Structural studies of murine lymphocyte surface IgD. J Immunol. 1980 May;124(5):2082–2088. [PubMed] [Google Scholar]
  25. Helenius A., Marquardt T., Braakman I. The endoplasmic reticulum as a protein-folding compartment. Trends Cell Biol. 1992 Aug;2(8):227–231. doi: 10.1016/0962-8924(92)90309-b. [DOI] [PubMed] [Google Scholar]
  26. Hitzel C., van Endert P., Koch N. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain. J Immunol. 1995 Feb 1;154(3):1048–1056. [PubMed] [Google Scholar]
  27. Koch N., Sandrin M. S., Hämmerling G. J., Tada N., Kimura S., Hämmerling U. Monoclonal antibodies detect polymorphic determinants shared by I-A and I-E antigens. Mol Immunol. 1984 Apr;21(4):293–299. doi: 10.1016/0161-5890(84)90100-7. [DOI] [PubMed] [Google Scholar]
  28. Lampson L. A., Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980 Jul;125(1):293–299. [PubMed] [Google Scholar]
  29. Lanier L. L., Gutman G. A., Lewis D. E., Griswold S. T., Warner N. L. Monoclonal antibodies against rat immunoglobulin kappa chains. Hybridoma. 1982;1(2):125–131. doi: 10.1089/hyb.1.1982.1.125. [DOI] [PubMed] [Google Scholar]
  30. Lanzavecchia A., Reid P. A., Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature. 1992 May 21;357(6375):249–252. doi: 10.1038/357249a0. [DOI] [PubMed] [Google Scholar]
  31. Lemke H., Hämmerling G. J., Hämmerling U. Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/TL region in mice. Immunol Rev. 1979;47:175–206. doi: 10.1111/j.1600-065x.1979.tb00293.x. [DOI] [PubMed] [Google Scholar]
  32. Lippincott-Schwartz J., Yuan L. C., Bonifacino J. S., Klausner R. D. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell. 1989 Mar 10;56(5):801–813. doi: 10.1016/0092-8674(89)90685-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Long E. O., LaVaute T., Pinet V., Jaraquemada D. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide. J Immunol. 1994 Aug 15;153(4):1487–1494. [PubMed] [Google Scholar]
  34. Madden D. R., Gorga J. C., Strominger J. L., Wiley D. C. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature. 1991 Sep 26;353(6342):321–325. doi: 10.1038/353321a0. [DOI] [PubMed] [Google Scholar]
  35. Madden D. R., Gorga J. C., Strominger J. L., Wiley D. C. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell. 1992 Sep 18;70(6):1035–1048. doi: 10.1016/0092-8674(92)90252-8. [DOI] [PubMed] [Google Scholar]
  36. Mehringer J. H., Harris M. R., Kindle C. S., McCourt D. W., Cullen S. E. Characterization of fragments of the murine Ia-associated invariant chain. J Immunol. 1991 Feb 1;146(3):920–927. [PubMed] [Google Scholar]
  37. Momburg F., Neefjes J. J., Hämmerling G. J. Peptide selection by MHC-encoded TAP transporters. Curr Opin Immunol. 1994 Feb;6(1):32–37. doi: 10.1016/0952-7915(94)90030-2. [DOI] [PubMed] [Google Scholar]
  38. Nadimi F., Moreno J., Momburg F., Heuser A., Fuchs S., Adorini L., Hämmerling G. J. Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. Eur J Immunol. 1991 May;21(5):1255–1263. doi: 10.1002/eji.1830210524. [DOI] [PubMed] [Google Scholar]
  39. Neefjes J. J., Ploegh H. L. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. EMBO J. 1992 Feb;11(2):411–416. doi: 10.1002/j.1460-2075.1992.tb05069.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Neefjes J. J., Ploegh H. L. Intracellular transport of MHC class II molecules. Immunol Today. 1992 May;13(5):179–184. doi: 10.1016/0167-5699(92)90123-O. [DOI] [PubMed] [Google Scholar]
  41. Newcomb J. R., Cresswell P. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers. J Immunol. 1993 Jan 15;150(2):499–507. [PubMed] [Google Scholar]
  42. Nijenhuis M., Calafat J., Kuijpers K. C., Janssen H., de Haas M., Nordeng T. W., Bakke O., Neefjes J. J. Targeting major histocompatibility complex class II molecules to the cell surface by invariant chain allows antigen presentation upon recycling. Eur J Immunol. 1994 Apr;24(4):873–883. doi: 10.1002/eji.1830240415. [DOI] [PubMed] [Google Scholar]
  43. Peccoud J., Dellabona P., Allen P., Benoist C., Mathis D. Delineation of antigen contact residues on an MHC class II molecule. EMBO J. 1990 Dec;9(13):4215–4223. doi: 10.1002/j.1460-2075.1990.tb07869.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rippmann F., Taylor W. R., Rothbard J. B., Green N. M. A hypothetical model for the peptide binding domain of hsp70 based on the peptide binding domain of HLA. EMBO J. 1991 May;10(5):1053–1059. doi: 10.1002/j.1460-2075.1991.tb08044.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Roche P. A., Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature. 1990 Jun 14;345(6276):615–618. doi: 10.1038/345615a0. [DOI] [PubMed] [Google Scholar]
  46. Roche P. A., Teletski C. L., Karp D. R., Pinet V., Bakke O., Long E. O. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR. EMBO J. 1992 Aug;11(8):2841–2847. doi: 10.1002/j.1460-2075.1992.tb05351.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rothbard J. B., Gefter M. L. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol. 1991;9:527–565. doi: 10.1146/annurev.iy.09.040191.002523. [DOI] [PubMed] [Google Scholar]
  48. Sadegh-Nasseri S., Germain R. N. How MHC class II molecules work: peptide-dependent completion of protein folding. Immunol Today. 1992 Feb;13(2):43–46. doi: 10.1016/0167-5699(92)90131-P. [DOI] [PubMed] [Google Scholar]
  49. Schaiff W. T., Hruska K. A., Jr, McCourt D. W., Green M., Schwartz B. D. HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells. J Exp Med. 1992 Sep 1;176(3):657–666. doi: 10.1084/jem.176.3.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Schild H., Mavaddat N., Litzenberger C., Ehrich E. W., Davis M. M., Bluestone J. A., Matis L., Draper R. K., Chien Y. H. The nature of major histocompatibility complex recognition by gamma delta T cells. Cell. 1994 Jan 14;76(1):29–37. doi: 10.1016/0092-8674(94)90170-8. [DOI] [PubMed] [Google Scholar]
  51. Schmid S. L., Jackson M. R. Immunology. Making class II presentable. Nature. 1994 May 12;369(6476):103–104. doi: 10.1038/369103a0. [DOI] [PubMed] [Google Scholar]
  52. Sette A., Adorini L., Colon S. M., Buus S., Grey H. M. Capacity of intact proteins to bind to MHC class II molecules. J Immunol. 1989 Aug 15;143(4):1265–1267. [PubMed] [Google Scholar]
  53. Shastri N., Malissen B., Hood L. Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5885–5889. doi: 10.1073/pnas.82.17.5885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Simonsen A., Momburg F., Drexler J., Hämmerling G. J., Bakke O. Intracellular distribution of the MHC class II molecules and the associated invariant chain (Ii) in different cell lines. Int Immunol. 1993 Aug;5(8):903–917. doi: 10.1093/intimm/5.8.903. [DOI] [PubMed] [Google Scholar]
  55. Stockinger B., Pessara U., Lin R. H., Habicht J., Grez M., Koch N. A role of Ia-associated invariant chains in antigen processing and presentation. Cell. 1989 Feb 24;56(4):683–689. doi: 10.1016/0092-8674(89)90590-4. [DOI] [PubMed] [Google Scholar]
  56. Teyton L., O'Sullivan D., Dickson P. W., Lotteau V., Sette A., Fink P., Peterson P. A. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature. 1990 Nov 1;348(6296):39–44. doi: 10.1038/348039a0. [DOI] [PubMed] [Google Scholar]
  57. Thibodeau J., Cloutier I., Lavoie P. M., Labrecque N., Mourad W., Jardetzky T., Sékaly R. P. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science. 1994 Dec 16;266(5192):1874–1878. doi: 10.1126/science.7997881. [DOI] [PubMed] [Google Scholar]
  58. Viville S., Neefjes J., Lotteau V., Dierich A., Lemeur M., Ploegh H., Benoist C., Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell. 1993 Feb 26;72(4):635–648. doi: 10.1016/0092-8674(93)90081-z. [DOI] [PubMed] [Google Scholar]
  59. Watanabe M., Suzuki T., Taniguchi M., Shinohara N. Monoclonal anti-Ia murine alloantibodies crossreactive with the Ia-homologues of other mammalian species including humans. Transplantation. 1983 Dec;36(6):712–718. doi: 10.1097/00007890-198336060-00025. [DOI] [PubMed] [Google Scholar]
  60. Wettstein D. A., Boniface J. J., Reay P. A., Schild H., Davis M. M. Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH. J Exp Med. 1991 Jul 1;174(1):219–228. doi: 10.1084/jem.174.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Winslow G. M., Scherer M. T., Kappler J. W., Marrack P. Detection and biochemical characterization of the mouse mammary tumor virus 7 superantigen (Mls-1a). Cell. 1992 Nov 27;71(5):719–730. doi: 10.1016/0092-8674(92)90549-r. [DOI] [PubMed] [Google Scholar]